Dr Lenka Munoz

Senior Lecturer
Pharmacology, School of Medical Sciences

Telephone +61 2 9351 2315
Fax +61 2 9351 3868

Map

Selected grants

2015

  • Preparative High-Performance Liquid Chromatograph (Preparative-HPLC) for Expediting Drug Translation; Codd R, Payne R, Kassiou M, Groundwater P, Munoz L; DVC Research/Equipment Grant.
  • SMSF Grant 2015 Munoz; Munoz L; Sydney Medical School/Research Support.

2013

  • Improving chemotherapy response rates in brain cancer; Munoz L; Sydney Foundation for Medical Research/Research Support.
  • Development of small molecule inhibitors of LRRK2 for treatment of Parkinsons disease; Kassiou M, Munoz L; Parkinson's New South Wales Incorporated/Research Support.
  • A novel approach to overcome chemotherapy resistance in glioblastoma; Munoz L; DVC Research/Brown Fellowships.

2009

  • Integrating chemistry and biology in the search for new therapeutics for Alzheimer's disease; Munoz L; Judith Jane Mason and Harold Stannett Williams Memorial Foundation/Medical and Scientific Research Grants.
  • Integrating Chemistry and Biology in the Search for New Therapeutics for Alzheimer's disease; Munoz L, Ammit A, Guillemin G, Guillemin G; Alzheimers Australia/Dementia Grants Program.

2008

  • Targeting inactive p38alpha kinase as a strategy to treat rheumatoid arthritis; Munoz L; Arthritis Foundation of Australia/Research Support.
  • Discovery of novel drugs to treat alzheimers disease; Munoz L; Rebecca L Cooper Medical Research Foundation/Research Support.
  • Targeting inactive p38a MAPK as a novel strategy to treat neurodegenerative disorders; Munoz L, Peifer C; Deutscher Akademischer Austausch Dienst (DAAD)/Travelling Fellowship.
  • Will Selective p38 MAPK Inhibitor Prevent Brain Tumour Progression and Metastasis; Munoz L; Cure for Life Foundation/Research Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gurgis, F., Ziaziaris, W., Munoz, L. (2014). Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation and Cell Cycle: Role and Targeting. Molecular Pharmacology, 85(2), 345-356. [More Information]
  • Yeung, Y., McDonald, K., Grewal, T., Munoz, L. (2013). Interleukins in glioblastoma pathophysiology: implications for therapy. British Journal of Pharmacology, 168(3), 591-606. [More Information]
  • Eibl, C., Tomassoli, I., Munoz, L., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. Bioorganic and Medicinal Chemistry, 21(23), 7283-7308. [More Information]
  • Eibl, C., Munoz, L., Tomassoli, I., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicylo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. Bioorganic and Medicinal Chemistry, 21(23), 7309-7329. [More Information]
  • Yeung, Y., Bryce, N., Adams, S., Braidy, N., Konayagi, M., McDonald, K., Teo, C., Guillemin, G., Grewal, T., Munoz, L. (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Journal of Neuro-Oncology, 109(1), 35-44. [More Information]
  • Munoz, L., Selig, R., Yeung, Y., Peifer, C., Hauser, D., Laufer, S. (2010). Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. Analytical Biochemistry, 401(1), 125-133. [More Information]
  • Munoz, L., Ramsay, E., Manetsch, M., Ge, Q., Peifer, C., Laufer, S., Ammit, A. (2010). Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology, 635, 212-218. [More Information]
  • Munoz, L., Ammit, A. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 58(3), 561-568. [More Information]
  • Munoz, L., Ranaivo, H., Roy, S., Hu, W., Craft, J., McNamara, L., Chico, L., Van Eldik, L., Watterson, D. (2007). A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation, 4(21), Published online 2007 September 4. doi: 10.1186/17.
  • Hu, W., Ranaivo, H., Roy, S., Behanna, H., Wing, L., Munoz, L., Guo, L., Van Eldik, L., Watterson, D. (2007). Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(2), 414-418. [More Information]
  • Gundisch, D., Andrä, M., Munoz, L., Tilotta, M. (2004). Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 12, 4953-4962. [More Information]
  • Munoz, L., Laitinen, L., Raiman, J., Cizmarik, J., Sedlárová, E., Hirvonen, J. (2002). Permeability Profiles of M-Alkoxysubstituted Pyrrolidinoethylesters of Phenylcarbamic Acid across Caco-2 Monolayers and Human Skin. Pharmaceutical Research, 19(2), 162-168.
  • Munoz, L., Sedlárová, E., Cizmarik, J. (2002). Study of Local Anaesthetics, Part 156: Some Physicochemical and Lipophilic Properties of Pyrrolidinoethyl Esters of o-, m-, p-Alkoxy-Substituted Phenylcarbamic Acid. Chemical Papers, 56(5), 340-344.

2014

  • Gurgis, F., Ziaziaris, W., Munoz, L. (2014). Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation and Cell Cycle: Role and Targeting. Molecular Pharmacology, 85(2), 345-356. [More Information]

2013

  • Yeung, Y., McDonald, K., Grewal, T., Munoz, L. (2013). Interleukins in glioblastoma pathophysiology: implications for therapy. British Journal of Pharmacology, 168(3), 591-606. [More Information]
  • Eibl, C., Tomassoli, I., Munoz, L., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. Bioorganic and Medicinal Chemistry, 21(23), 7283-7308. [More Information]
  • Eibl, C., Munoz, L., Tomassoli, I., Stokes, C., Papke, R., Gundisch, D. (2013). The 3,7-diazabicylo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. Bioorganic and Medicinal Chemistry, 21(23), 7309-7329. [More Information]

2012

  • Yeung, Y., Bryce, N., Adams, S., Braidy, N., Konayagi, M., McDonald, K., Teo, C., Guillemin, G., Grewal, T., Munoz, L. (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Journal of Neuro-Oncology, 109(1), 35-44. [More Information]

2010

  • Munoz, L., Selig, R., Yeung, Y., Peifer, C., Hauser, D., Laufer, S. (2010). Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. Analytical Biochemistry, 401(1), 125-133. [More Information]
  • Munoz, L., Ramsay, E., Manetsch, M., Ge, Q., Peifer, C., Laufer, S., Ammit, A. (2010). Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology, 635, 212-218. [More Information]
  • Munoz, L., Ammit, A. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 58(3), 561-568. [More Information]

2007

  • Munoz, L., Ranaivo, H., Roy, S., Hu, W., Craft, J., McNamara, L., Chico, L., Van Eldik, L., Watterson, D. (2007). A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation, 4(21), Published online 2007 September 4. doi: 10.1186/17.
  • Hu, W., Ranaivo, H., Roy, S., Behanna, H., Wing, L., Munoz, L., Guo, L., Van Eldik, L., Watterson, D. (2007). Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(2), 414-418. [More Information]

2004

  • Gundisch, D., Andrä, M., Munoz, L., Tilotta, M. (2004). Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 12, 4953-4962. [More Information]

2002

  • Munoz, L., Laitinen, L., Raiman, J., Cizmarik, J., Sedlárová, E., Hirvonen, J. (2002). Permeability Profiles of M-Alkoxysubstituted Pyrrolidinoethylesters of Phenylcarbamic Acid across Caco-2 Monolayers and Human Skin. Pharmaceutical Research, 19(2), 162-168.
  • Munoz, L., Sedlárová, E., Cizmarik, J. (2002). Study of Local Anaesthetics, Part 156: Some Physicochemical and Lipophilic Properties of Pyrrolidinoethyl Esters of o-, m-, p-Alkoxy-Substituted Phenylcarbamic Acid. Chemical Papers, 56(5), 340-344.

To update your profile click here. For support on your academic profile contact .